Prospects of Schizophrenia Relapse Pharmacotherapy Research: Bench or Bedside?
Pharmacy & Pharmacology International Journal · 2015
DOI: 10.15406/ppij.2015.02.00011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacy & Pharmacology International Journal, 2015. Verfasst von Kris Ramabadran. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
In pharmacotherapy of schizophrenia, as a class, antipsychotic drugs have remained as mainstay since 1950s. Accumulating data of suboptimal outcomes and multiple adverse effects associated with therapy using the first-generation (“conventional/typical”) antipsychotic drugs compelled adopting the classic route of bench research to explore New Molecular Entity [NME] with potential to be more effective and safe and lead to the development of multiple second-generation (“atypical”) antipsychotic drugs. At present, although many second-generation antipsychotic drugs are available for prescription, few differences exist among them in their short-term efficacy [5]. Moreover, some comparative data analyses of efficacy and tolerability of antipsychotic drugs in schizophrenia appear to challenge the straightforward classification of antipsychotics into first-generation and secondgeneration categories [6].
Zitieren
APA
Ramabadran, K. (2015). Prospects of Schizophrenia Relapse Pharmacotherapy Research: Bench or Bedside?. Pharmacy & Pharmacology International Journal. https://doi.org/10.15406/ppij.2015.02.00011
Vancouver
Ramabadran K. Prospects of Schizophrenia Relapse Pharmacotherapy Research: Bench or Bedside?. Pharmacy & Pharmacology International Journal. 2015. doi:10.15406/ppij.2015.02.00011
BibTeX
@article{Ramabadran2015,
author = {Ramabadran, Kris},
title = {Prospects of Schizophrenia Relapse Pharmacotherapy Research: Bench or Bedside?},
journal = {Pharmacy & Pharmacology International Journal},
year = {2015},
doi = {10.15406/ppij.2015.02.00011}
}
EUVIMED